Durvalumab immune checkpoint inhibition  

Imfinzi - durvalumab      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

lung cancer (metastatic)  

PACIFIC, 2017      NCTdurvalumabplacebomaintenance maintenance therapy Low risk of bias conclusive-48%
ARCTIC PD-L1 negative, 2018    NCTdurvalumab + tremelimumabStandard of Care3L, PD-L1 negative -

urothelial carcinoma (advanced)  

durvalumab phase 1/2 single-arm   durvalumabnil2nd line 2nd line Exploratory -